Third Quarter Conference Calls, In Brief
Executive Summary
Pfizer Spiriva production: Boehringer-Ingelheim "has sufficient manufacturing capacity already in Germany" to meet demand for the chronic obstructive pulmonary drug Spiriva (tiotropium) "for out as far as we can see," Pfizer CEO Henry McKinnell tells Oct. 17 conference call. Pfizer will copromote the BI agent, with launch expected in 2002 or 2003. BI's Columbus, Ohio facility "was to come on stream for production in 2005," McKinnell noted. The plant was the subject of an FDA warning letter in July (1"The Pink Sheet" July 30, p. 10)...
You may also be interested in...
Forest Expects Memantine NDA In June; Readies For Benicar Sampling
Forest expects to submit an NDA for the Alzheimer's drug memantine in June, the company told analysts at the Deutsche Bank healthcare conference in Baltimore May 7
Forest Expects Memantine NDA In June; Readies For Benicar Sampling
Forest expects to submit an NDA for the Alzheimer's drug memantine in June, the company told analysts at the Deutsche Bank healthcare conference in Baltimore May 7
Bristol Inventory Issues Include High Supply Of Glucophage IR
Bristol-Myers Squibb's new approach to wholesaler inventory levels should help the company capture more of the benefit from product price increases, CEO Peter Dolan suggested during an April 25 earnings conference call